latest news releases from the newsroom
Atlas Copco consolidates its construction tool business
STOCKHOLM, Sweden, Oct. 30, 2003 (PRIMEZONE) --Atlas Copco Construction Tools, a division within the Atlas Copco Group, has announced a reorganization of its operation in Essen, Germany. The reasons are the prevailing market conditions in the construction industry, and a further implementation of synergies between its operations, aimed at an increased efficiency. Approximately 80 jobs in Germany are affected.
Pyrosequencing finalizes acquisition of Biotage
UPPSALA, Sweden, Oct. 30, 2003 (PRIMEZONE) -- Pyrosequencing AB (Stockholm:PYROA) today announced that the Company has finalized the acquisition of Biotage, as announced on October 14, through a cash payment of 235 MSEK and taking over a mortgage of 36 MSEK, relating to the premises in Virginia, U.S. Pyrosequencing now owns 100 percent of the shares in Biotage.
Celltech Group plc
Celltech: Re. Licensing Deal
SLOUGH, U.K., Oct. 30, 2003 (PRIMEZONE) -- Celltech Pharmaceuticals, a division of Celltech Group plc (LSE:CCH) (NYSE:CLL), announces that it has licensed European sales and marketing rights to Xyrem (sodium oxybate) oral solution from Orphan Medical, Inc. (Nasdaq:ORPH). Orphan Medical received U.S. FDA approval in July 2002 to market Xyrem as a treatment for cataplexy in patients with narcolepsy. Cataplexy is a sudden loss of muscular control triggered by amusement, anger or excitement, resulting in dropping of the jaw, head slumping, leg buckling and even whole body collapse, and is estimated to affect 60-90% of narcoleptic patients. Celltech expect to file a Xyrem marketing authorisation application for the cataplexy indication in Europe in early 2004 and, upon approval, will use its specialist sales forces to market the product to the target audience of neurologists and sleep specialists.